Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Iluvien Now Widely Available To DME Patients Throughout U.S.

April 22, 2015 11:54 am | News | Comments

Alimera Sciences, Inc. (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using Iluvien. Read more..

With Bird Flu Spreading, USDA Starts on Potential Vaccine

April 22, 2015 11:47 am | by Steve Karnowski, Associated Press | News | Comments

The U.S. Department of Agriculture is working on a vaccine to counter a deadly strain of bird flu, as losses to poultry producers mount. Read more...p


AACR 2015: Pembrolizumab Comes Out on Top for Melanoma, Lung Cancer

April 22, 2015 10:33 am | by Stephanie Guzowski, Editor | Articles | Comments

At the AACR Annual Meeting 2015, immunotherapies, called PD-1 inhibitors, were front and center stage, due to clinical trial results that led to U.S. Food and Drug Administration (FDA) approvals for treating melanoma and non-small cell lung cancer (NSCLC). Read more..


Regulatory and Clinical Factors Limiting U.S. Non-Vascular Stent Market Growth

April 22, 2015 9:43 am | by Priya Radhakrishnan, Director of Medical Devices, GlobalData | News | Comments

The future growth of the non-vascular stent market by 2021 will be slower in the US than almost every other major market, due in part to an increasingly difficult regulatory process and the medical device excise tax, but primarily as a result of clinical factors and unmet needs still to be addressed, said research and consulting firm GlobalData. Read more...


Takeda: Research Collaboration with Keio University School of Medicine, Niigata University

April 21, 2015 3:36 pm | News | Comments

This will focus on the search for and functional analysis of disease-related RNA-binding proteins. Read more...


GW Pharmaceuticals Initiates Second Phase 3 Trial for Epidiolex

April 21, 2015 3:15 pm | News | Comments

This drug is intended for the treatment of Dravet syndrome. Read more...


Lupin Launches Zaxine in Canada

April 21, 2015 3:08 pm | News | Comments

The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in Canada. Read more...


Trial Shows Benefit of 'BRCA-targeting' Drug in Prostate Cancer

April 21, 2015 3:00 pm | by Institute of Cancer Research | News | Comments

Men with prostate cancer benefit from treatment with the pioneering drug olaparib. Read more...


Teva Offers to Buy Mylan in $40.1B Cash and Stock Deal

April 21, 2015 2:49 pm | by Linda A. Johnson, AP Business Writer | News | Comments

Generic drug giant Teva formally offered to buy fellow drugmaker Mylan about $40.1 billion in cash and stock on Tuesday. Read more...


Pfizer: FDA Breakthrough Therapy Designation for Lung Cancer Drug

April 21, 2015 11:57 am | News | Comments

Pfizer Inc. announced today that Xalkori (crizotinib) received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). Read more...


Scientists Turn Cancer Cells into Normal Cells

April 21, 2015 11:49 am | by Sanford-Burnham Medical Research Institute | News | Comments

A new research study has shown that pancreatic cancer cells can be coaxed to revert back toward normal cells by introducing a protein called E47. E47 binds to specific DNA sequences and controls genes involved in growth and differentiation. Read more...


Genetic Variance Explains Poor Response to Asthma Medications

April 21, 2015 11:42 am | News | Comments

Researchers have identified a biological basis for asthmatic children who do not respond well to corticosteroid treatment - currently the most effective treatment for chronic asthma and acute asthma attack. Read more...


Merck, Pfizer Initiate Phase 3 Avelumab Study

April 21, 2015 11:26 am | News | Comments

Merck and Pfizer today announced the initiation and first patient treated in the international Phase 3 study (EMR 100070-004) designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab. Read more...


A New Lease on Life for Prostate Tissue

April 21, 2015 11:19 am | by Rutgers University | News | Comments

What if a prostate cancer patient could learn which anti-cancer treatments would work best for him without having to swallow a single pill or endure a single intravenous line or injection? Read more...


No Link Between Vaccine and Autism, Massive Study Says

April 21, 2015 11:06 am | by Seth Augenstein, Digital Reporter | News | Comments

A massive new study has found no link between a common vaccine and autism, researchers announced today. The study is the latest among years of research projects which make no connection between inoculations and an increased risk for the autism spectrum, the researchers said. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.